CorMedix Inc(CRMD) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 7:58 PM ET (Korea 10/31 08:58)
Full metrics table
| Index | RUT | P/E | 2.71 | EPS (ttm) | 2.1 | Insider Own | 8.29% | Shs Outstand | 77.7M | Perf Week | -27.45% |
| Market Cap | 0.44B | Forward P/E | 82.63 | EPS next Y | -86.09% | Insider Trans | - | Shs Float | 71.5M | Perf Month | -23.25% |
| Enterprise Value | 0.33B | PEG | - | EPS next Q | -0.11 | Inst Own | 56.92% | Short Float | 20.52% | Perf Quarter | -24.57% |
| Income | 0.19B | P/S | 0.96 | EPS this Y | -75.71% | Inst Trans | 2.7% | Short Ratio | 12.92 | Perf Half Y | -26.89% |
| Sales | 0.46B | P/B | 0.96 | EPS next 5Y | - | ROA | 32.36% | Short Interest | 14.67M | Perf YTD | -51.03% |
| Book/sh | 5.93 | P/C | 1.72 | EPS past 3/5Y | - | ROE | 54.93% | 52W High | -56.26% ($13.02) | Perf Year | -50.99% |
| Cash/sh | 3.3 | P/FCF | 1.77 | Sales past 3/5Y | 1582.83% 319.75% | ROIC | 30.89% | 52W Low | -7.02% ($6.12) | Perf 3Y | 78.53% |
| Dividend Est. | - | EV/EBITDA | 1.31 | EPS Y/Y TTM | 210.82% | Gross Margin | 82.78% | Volatility(W/M) | 12.15% 5.7% | Perf 5Y | 17.18% |
| Dividend TTM | - | EV/Sales | 0.72 | Sales Y/Y TTM | 280.5% | Oper. Margin | 46.95% | ATR (14) | 0.45 | Perf 10Y | -47.02% |
| Dividend Ex-Date | - | Quick Ratio | 2.36 | EPS Q/Q | 1.92% | Profit Margin | 40.49% | RSI (14) | 25.27 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.56 | Sales Q/Q | 156.52% | SMA20 | -23.89% ($7.49) | Beta | 1.44 | Target Price | $14.6 |
| Payout | - | Debt/Eq | 0.31 | Earnings | 2026/8/13 | SMA50 | -26.97% ($7.81) | Rel Volume | 6.18 | Prev Close | $7.64 |
| Employees | 191 | LT Debt/Eq | 0.31 | EPS/Sales Surpr. | 21.85% 6.13% | SMA200 | -25.77% ($7.68) | Avg Volume(3M) | 1.14M | Price | $5.7 |
| IPO | 2010/5/13 | Option/Short | Yes/Yes | Trades | 19740 | Volume | 7,016,611 | Change | -25.46% |
🩺 CorMedix (CRMD) is a U.S. biotech company specializing in the prevention of catheter-related bloodstream infections (CRBSIs). Its flagship product, DefenCath, is a catheter lock solution that combines the antimicrobial agent taurolidine with the anticoagulant heparin, and is used to reduce the risk of infection in hemodialysis patients. CorMedix is an infection-prevention-focused company that holds the first and only antimicrobial catheter lock solution of its kind approved in the United States.
Over the past 1 year, on the lower side
56% below its 1-year high.
Traded more than usual. That is 618% of its average volume.
CRMD makes money exceptionally well
Of every $100 in sales, $46.95 is kept as operating profit.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -75.7% this year.
Tap to view numbers
The price is about the industry average
For a company earning $100 a year, you would pay $271. Peers typically go for $749. Compared with its own 1-year average, it is 33% cheaper now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be +17.2%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Short interest is a burden
20.5% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #226 of 597 in the industry
Based on market cap of $444M.
FAQ
What kind of company is CRMD?
CRMD belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of CRMD?
The market cap of CRMD is approximately $444M, ranking 3,243 within its sector.
What is the P/E ratio of CRMD?
CRMD has a P/E ratio of approximately 2.7x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for CRMD?
CRMD has recorded a 52-week high of $13.02 and a low of $6.12.
